- GERN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.6 million.
- GERN has traded 402,333 shares today.
- GERN is down 3.9% today.
- GERN was up 25.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in GERN with the Ticky from Trade-Ideas. See the FREE profile for GERN NOW at Trade-Ideas More details on GERN: Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Currently there are 2 analysts that rate Geron a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Geron has been 2.0 million shares per day over the past 30 days. Geron has a market cap of $349.9 million and is part of the health care sector and drugs industry. The stock has a beta of 2.30 and a short float of 21.7% with 5.86 days to cover. Shares are down 40.9% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
TheStreetRatings.com Analysis:TheStreet Quant Ratings rates Geron as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Highlights from the ratings report include:
- GERN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 39.95%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- The company, on the basis of net income growth from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Biotechnology industry average. The net income increased by 2.4% when compared to the same quarter one year prior, going from -$8.95 million to -$8.73 million.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, GERON CORP's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has increased to -$5.15 million or 35.03% when compared to the same quarter last year. In addition, GERON CORP has also vastly surpassed the industry average cash flow growth rate of -49.44%.
- GERN has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 29.94, which clearly demonstrates the ability to cover short-term cash needs.
- You can view the full Geron Ratings Report.